Abstract:Background: Bladder cancer (BC), as a common type of cancer, has a poor prognosis, also some common invasive prognostic or therapeutic markers are difficult to obtain, which makes further treatment of BC difficult. Glycyl-tRNA synthetase (GARS), as one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids, has been identified as a target in many diseases, including tumors. Methods: Bioassay analysis revealed that GARS was in high expression in most cancer tissues. The expression of GARS gene in BC tissues could assess the prognosis of BC patients, and the expression in urinary extracellular vesicles (uEVs) of patients was positively correlated with the expression in tissues. In addition to this, we analyzed GARS-related differential gene expression, copy number variation (CNV) and mutation profiles, potential biological functions, immune cell infiltration and drug sensitivity. In vivo and vitro tumorigenic experiments were performed to validate the function of GARS. Single-cell data were used to further analyze its role in the microenvironment. Results: In our study, we found that GARS was highly expressed in 30 cancer tissues including BC, and high GARS expression was negatively correlated with the prognosis of BC patients. To address this phenomenon, we analyzed the differential genes between high and low GARS groups by enrichment analysis, and identified the biological signaling pathways that were mainly enriched for their functions, and found that the enrichment was found in immune-related signaling pathways and regulation of cell-cell adhesion. Then we found that GARS was positively associated with immune cell infiltration in BC, and some common immune checkpoints were significantly overexpressed in the GARS-high group. Besides, we found that GARS was enriched in myofibroblasts in the tumor microenvironment, and the enrichment was positively correlated with epithelial-mesenchymal transition (EMT)-related genes. This study also showed a positive correlation between GARS and BC RNA stemness. Patients in the GARS-high group had considerably higher rates of P53 and Titin (TTN) mutations than those in the GARS-low group. Drug Sensitivity analysis screened for drugs that were more sensitive to GARS-high patients. Further, we found that knockdown of GARS significantly inhibited the proliferation, migration and invasion ability both in vivo and in vitro. Finally, we found that in patients with high GARS the expression in uEVs was also at a high level. Conclusions: In summary, this study provided evidence that GARS can be used as a prognostic and therapeutic marker for BC, we can detect GARS in uEVs instead of tissue, to provide a new, simple, noninvasive way to obtain prognostic and therapeutic markers for BC patients.

Gabarap is Overexpressed in Colorectal Carcinoma and Correlates with Shortened Patient Survival

Neuronal Protein Synuclein Gamma Predicts Poor Clinical Outcome in Breast Cancer

High GP73 Expression Correlates with Poor Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer: A Tissue Microarray Study.

Low Expression of GABARAPL1 is Associated with a Poor Outcome for Patients with Hepatocellular Carcinoma.

Comprehensive Analysis of the Expression, Prognostic Value, and Immune Infiltration Activities of GABRD in Colon Adenocarcinoma

Expression of Neuronal Protein Synuclein Gamma Gene As a Novel Marker for Breast Cancer Prognosis

GABRP is a potential prognostic biomarker and correlated with immune infiltration and tumor microenvironment in pancreatic cancer

Overexpression of Glucose-Regulated Protein 78 in Colon Cancer.

Gab2 Signaling in Breast Cancer

Diagnostic and Prognostic implications of AAGAB expression in human breast cancer

ROR alpha and REV-ERB alpha are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer

High Expression of ERK-related RASGRF2 Predicts Poor Prognosis in Patients with Stomach Adenocarcinoma and Correlates with M2 Macrophage

Gene Expression of GABAA Receptor Subunits and Association with Patient Survival in Glioma

Expression Pattern and Clinical Significance of Gab2 Protein in Hepatocellular Carcinoma.

Elevated Expression of Gab1 Promotes Breast Cancer Metastasis by Dissociating the PAR Complex

Expressions and Clinical Significance of Met and YAP in Gastric Cancer Tissue Microarray

Expression of Signaling Adaptor Proteins Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma

GABARAPL1 negatively regulates Wnt/β-catenin signaling by mediating Dvl2 degradation through the autophagy pathway.

Elevated Ras Related GTP Binding B (RRAGB) Expression Predicts Poor Overall Survival and Constructs a Prognostic Nomogram for Colon Adenocarcinoma

Prognostic value of GARS in bladder cancer and its role in the tumor microenvironment